Skip to NavigationSkip to content

Johnson & Johnson

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy of its SGLT2 inhibitor Invokana (canagliflozin), but not because it had proved ineffective.

On the contrary, after the drug met its pre-specified efficacy criteria in the prevention of clinically important renal and cardiovadcvular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the company deemed it pertinent to close the study early.

J&J's second-in-command to retire, alongside executive restructure

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the company effective 1 October this year, triggering and executive-level shift at the firm. Following her departure, the vacated role will be shared as of 2 July by Chief Scientific Officer Paul Stoffel and Joaquin Duato, leader of J&J’s global pharmaceuticals business, where they will both hold the title of Vice Chairman.

J&J continues to shed assets, with $2.1bn diabetes unit sale

Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, potentially bringing in $2.8 billion. It has now revealed that it has accepted a $2.1 billion offer for LifeScan from Platinum Equity.

J&J actually received the first offer back in March and were given a deadline of mid-June to decide whether to accept the offer.

J&J looks to trim business with $2.8bn sale

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive to sell its medical-sterilisation unit for $2.8 billion.

The deal consists of $2.7 billion in cash and $0.1 billion of retained net receivables.

For J&J, it is trying to divest units that have slower growth compared to the rest of the business. After its $30 billion deal for Actelion, it is clearly trying to focus on the higher growth area of pharmaceuticals into the long-term.

Celgene bring in new CFO to steady the ship

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing serious questions over its pipeline and major worries about its lead candidate, ozanimod.

Behind this drama has been a steadily revolving door of executive exits from the company, as it attempts to display to its shareholders that it is taking a fresh approach to business. It needs to demonstrate this if it is to shore up its share price, which is significantly down from where it stood in October last year ($146 down to $79, at present).

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in patients with previously treated non-small cell lung cancer.

J&J's ketamine-based antidepressant showed mixed success at Phase 3

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled anaesthetic often used recreationally, painting a mixed picture of its efficacy.

J&J’s ketamine nasal spray for depression continues to impress

New treatments for depression are few and far between; pharmaceutical companies have shied away from trying to develop new therapeutics due to the difficulty in overcoming the placebo effect in treating depression.

This is possibly why researchers and companies are now looking to existing compounds, which have previously not been investigated due to their reputation as party drugs.

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

Published on 12/04/18 at 10:11am

Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen's EMEA operations to discuss nearly three decades at the company, and what continues to drive his work.

How did your father’s profession as a physician and your early life influence the career path you eventually chose?

J&J pays out $37m in damages over claims its talc contains asbestos

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out $37 million in damages after losing the first trial in a legal dispute which alleges that its Baby Powder product contains the carcinogenic ingredient asbestos.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches